TME Pharma NV (FRA:0N6A) OCF Margin %: 2,085.19% (As of Dec. 2025)


What is TME Pharma NV OCF Margin %?

TME Pharma NV FRA:0N6A -7.85% OCF Margin % is 2,085.19% as of Dec. 2025. The stock has 4 warning signs investors should review. Among 960 Biotechnology companies, TME Pharma NV ranks worse than 104166.56% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. TME Pharma NV's Cash Flow from Operations for the six months ended in Dec. 2025 was €-0.56 Mil. TME Pharma NV's Revenue for the six months ended in Dec. 2025 was €-0.03 Mil. Therefore, TME Pharma NV's OCF Margin % for the quarter that ended in Dec. 2025 was 2,085.19%.

As of today, TME Pharma NV's current OCF Yield % is -49.58%.

The historical rank and industry rank for TME Pharma NV's OCF Margin % or its related term are showing as below:


During the past 12 years, the highest OCF Margin % of TME Pharma NV was -10832.53%. The lowest was -10832.53%. And the median was -10832.53%.

FRA:0N6A's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -68.59
* Ranked among companies with meaningful OCF Margin % only.

TME Pharma NV OCF Margin % Related Terms

TME Pharma NV OCF Margin % Historical Data

* Premium members only.

The historical data trend for TME Pharma NV's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TME Pharma NV OCF Margin % Chart

TME Pharma NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TME Pharma NV Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -10,592.59 2,085.19

TME Pharma NV OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

TME Pharma NV's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-3.423/0
= %

TME Pharma NV's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-0.563/-0.027
=2,085.19 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 2,085.19% mean?
TME Pharma NV (FRA:0N6A) has a OCF Margin % of 2,085.19% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on TME Pharma NV and its competitors. According to the industry distribution chart, TME Pharma NV ranks #999999 out of 960 companies in the Biotechnology industry.
Is TME Pharma NV's OCF Margin % too high?
TME Pharma NV's current OCF Margin % is 2,085.19%. Based on the distribution chart, TME Pharma NV ranks #999999 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does TME Pharma NV's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TME Pharma NV ranks #999999 out of 960 companies for OCF Margin %. This places TME Pharma NV in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on TME Pharma NV and its competitors. TME Pharma NV's current OCF Margin % is 2,085.19%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TME Pharma NV stock overvalued right now?
TME Pharma NV (FRA:0N6A) has a current OCF Margin % of 2,085.19%. The current OCF Margin % is 2,085.19%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For TME Pharma NV (FRA:0N6A), the current OCF Margin % is 2,085.19% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TME Pharma NV Business Description

Other Exchanges ALTME:France
Address Max-Dohrn-Strasse 8-10, Berlin, DEU, 10589
TME Pharma NV is a clinical-stage biopharmaceutical company focused on developing novel therapies for treatment of the aggressive cancers and specializing in approaches targeting the tumor microenvironment. Its enhances the effectiveness of cancer treatments including current standards of care (such as antivascular agents, chemotherapy and radiotherapy) and immune-oncology approaches (such as immune checkpoint inhibitors). The company's Spiegelmer platform has generated a proprietary pipeline of clinical-stage product candidates including its cancer drug candidate NOX-A12 and its second clinical-stage asset, NOX-E36, now planned to be developed in eye diseases. The company has one segment active in pioneering the development of a new class of proprietary therapeutics called Spiegelmers.